Newsfeeds - Spark Newswire

1 minute read

$100 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today

Today, 7:58 AM

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 3.6% on an annualized basis producing an average annual return of 14.41%. Currently, Novo Nordisk has a market capitalization of $258.15 billion.

NVO

1 minute read

With New Phase 3 Data From Its Hemophilia Study, Novo Nordisk Plots Route To FDA

By Vandana Singh

Today, 7:58 AM

Novo Nordisk A/S (NYSE:NVO) announced the phase 3 results of the explorer7 study, assessing the efficacy and safety of prophylactic treatment…

NVO

1 minute read

Novo Nordisk’s Mim8 Shows Potential As Once Monthly Treatment For Hemophilia A

By Vandana Singh

Today, 7:58 AM

Novo Nordisk A/S (NYSE:NVO) announced that the phase 1 & 2 FRONTIER1 dose-escalation study in treating people with hemophilia…

NVO

1 minute read

Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients

By Vandana Singh

Today, 7:58 AM

Sanofi SA (NASDAQ:SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply…

LLY

1 minute read

UBS Downgrades Novo Nordisk to Sell

By Benzinga Newsdesk

Today, 7:58 AM

UBS analyst Michael Leuchten downgrades Novo Nordisk (NYSE:NVO) from Neutral to Sell.

NVO

1 minute read

If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today

By Benzinga Insights

Today, 7:58 AM

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 3.35% on an annualized basis producing an average annual return of 14.11%. Currently, Novo Nordisk has a market capitalization of $238.19 billion.

NVO

1 minute read

Eli Lilly Presents New Analyses On Tirzepatide Injection For Type 2 Diabetes

By Vandana Singh

Today, 7:58 AM

Eli Lilly And Co (NYSE:LLY) presented new data from a mechanism of action study and new analyses of the global registration…

LLY

2 minute read

Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products –

By Charles Gross

Today, 7:58 AM

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo Nordisk, a leading global healthcare company, to create novel expression hosts for pharmaceutical products.

DNA